Sugi Predict

Sugi Predict / Compounds / SCHEMBL5711299

SCHEMBL5711299

SCHEMBL5711299

O=C(O)CC[C@H]1C(=O)OCN1C(=O)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.63
▸ PSEN1 P49768 1/20 0.48
▸ PSEN2 P49810 1/20 0.48
▸ APH1B Q8WW43 1/20 0.48
▸ NCSTN Q92542 1/20 0.48
▸ APH1A Q96BI3 1/20 0.48
▸ PSENEN Q9NZ42 1/20 0.48
▸ HTR2C P28335 1/20 0.44
▸ F2 P00734 2/20 0.43
▸ ELANE P08246 2/20 0.43
▸ CTSG P08311 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ NPSR1 Q6W5P4 1/20 0.43
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ PREP P48147 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3184957 1.00 USP2 (0.63) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711284 1.00 USP2 (0.63) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711279 0.93 USP2 (0.61) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711402 0.93 USP2 (0.61) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL7361266 0.92 USP2 (0.60) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5711333 0.92 USP2 (0.60) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL8013209 0.92 USP2 (0.65) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5324844 0.91 USP2 (0.59) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL5324841 0.91 USP2 (0.59) USP2PSEN1PSEN2APH1BNCSTN
SCHEMBL8842184 0.91 USP2 (0.64) USP2PSEN1PSEN2APH1BNCSTN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024040267-A2 DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF MITOKININ, INC. (US) 2024-02-22 — — WO claimed
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PEPTIDREAM INC (JP) 2026-01-15 — — US disclosed
EP-4534524-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF PeptiDream Inc. (JP) 2025-04-09 — — EP disclosed
WO-2024101402-A1 PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS 中外製薬株式会社 2024-05-16 — — WO disclosed
US-11912644-B2 Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate CELGENE CORPORATION (US) 2024-02-27 — — US disclosed
US-11912644-B2 Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate CELGENE CORPORATION (US) 2024-02-27 — — US disclosed
WO-2024040267-A2 DIRECT SYNTHESIS OF N-(3-SUBSTITUTED-CHROMAN-4-YL)-7H- PYRROLO[2,3-D]PYRIMIDIN-4-AMINES AND DERIVATIVES THEREOF MITOKININ, INC. (US) 2024-02-22 — — WO disclosed
WO-2023234425-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF ペプチドリーム株式会社 2023-12-07 — — WO disclosed
US-20230234914-A1 PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE CELGENE CORPORATION 2023-07-27 — — US disclosed
US-20230234914-A1 PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE CELGENE CORPORATION 2023-07-27 — — US disclosed
EP-0530506-B1 Optically active omega-halogen-2-amino alkanoic acids derivatives, process for their preparation and their use for the preparation of optically active phosphor-containing alpha-aminoacids HOECHST SCHERING AGREVO GMBH (DE) 1996-05-01 — — EP disclosed
EP-0652228-A1 Urethanes and ureas that induce cytokine production AMERICAN CYANAMID COMPANY (US) 1995-05-10 — — EP disclosed
EP-0530506-A1 Optically active omega-halogen-2-amino alkanoic acids derivatives, process for their preparation and their use for the preparation of optically active phosphor-containing alpha-aminoacids Hoechst Schering AgrEvo GmbH (DE) 1993-03-10 — — EP disclosed
EP-0182262-B1 NONA AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS SYNTEX (U.S.A.) INC. (US) 1993-01-20 — — EP disclosed
EP-0097031-B1 NONAPEPTIDE AND DECAPEPTIDE ANALOGS OF LHRH USEFUL AS LHRH ANTAGONISTS, THEIR PREPARATION AND COMPOSITIONS CONTAINING THEM SYNTEX (U.S.A.) INC. (US) 1988-09-21 — — EP disclosed
US-4690916-A ANTIFERTILITY AGENTS; HALO-SUBSTITUTED GUANADINO AMINO ACYL RESIDUE COMPONENT SYNTEX (U.S.A.) INC. (US) 1987-09-01 — — US disclosed
EP-0182262-A2 Nona and decapeptide analogs of LHRH useful as LHRH antagonists SYNTEX (U.S.A.) INC. (US) 1986-05-28 — — EP disclosed
US-4581169-A Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists SYNTEX (U.S.A.) INC. (US) 1986-04-08 — — US disclosed
US-4481190-A LUTEINIZING HORMONE RELEASING HORMONE SYNTEX (U.S.A.) INC. (US) 1984-11-06 — — US disclosed
EP-0097031-A2 Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists, their preparation and compositions containing them SYNTEX (U.S.A.) INC. (US) 1983-12-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230234914-A1 PROCESSES FOR THE PREPARATION OF (S)-TERT-BUTYL 4,5-DIAMINO-5-OXOPENTANOATE UMPS, DHPS, NT5C3B USP2 4058/4885PSEN1 4147/4885PSEN2 4201/4885
US-20260015313-A1 AMINO ACID ACTIVE ESTER AND SALT THEREOF NSUN3, BCAT1, SLC43A1 USP2 4448/4885PSEN1 4813/4885PSEN2 4842/4885
US-11912644-B2 Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate UMPS, DHPS, NT5C3B USP2 4058/4885PSEN1 4147/4885PSEN2 4201/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.